Pembrolizumab, another human monoclonal anti-PD-1 antibody, has been approved for the treatment of metastatic melanoma and sometimes for non-Hodgkin’s lymphoma and head and neck squamous cell carcinoma [84,85,86]. The gene discussed is PDCD1; the disease is metastatic melanoma.